

1. Original Articles

<Transporter-mediated Drug Disposition, Efficacy and Toxicity>

- 1) Fujita K, Masuo Y, Okumura H, Watanabe Y, Suzuki H, Sunakawa Y, Shimada K, Kawara K, Akiyama Y, Kitamura M, Kunishima M, Sasaki Y, Kato Y. Increased plasma concentrations of unbound SN-38, the active metabolite of irinotecan, in cancer patients with severe renal failure. *Pharm Res*, in press.
- 2) Shimizu T, Kijima A, Masuo Y, Ishimoto T, Sugiura T, Takahashi S, Nakamichi N, Kato Y. Gene ablation of carnitine/organic cation transporter 1 reduces gastrointestinal absorption of 5-aminosalicylate in mice. *Chem Pharm Bull* 38(5): 774-780, 2015.
- 3) Shimizu T, Masuo Y, Takahashi S, Nakamichi N and Kato Y. Organic Cation Transporter Octn1-mediated Uptake of Food-derived Antioxidant Ergothioneine into Infiltrating Macrophages during Intestinal Inflammation in Mice. *Drug Metab Pharmacokinet*, in press.
- 4) Ishimoto T, Nakamichi N, Hosotani H, Masuo Y, Sugiura T and Kato Y. Organic cation transporter-mediated ergothioneine uptake in mouse neural progenitor cells suppresses proliferation and promotes differentiation into neurons. *PLoS One* 9(2): e89434, 2014.
- 5) Takeuchi K, Sugiura T, Matsubara K, Sato R, Shimizu T, Masuo Y, Horikawa M, Nakamichi N, Ishiwata N and Kato Y. Interaction of novel platelet-increasing agent eltrombopag with rosuvastatin via breast cancer resistance protein in human. *Drug Metab Dispos* 42(4): 726-734, 2014. (IF₂₀₁₃ = 3.361)
- 6) Fujita K, Sugiura T, Okumura H, Umeda S, Nakamichi N, Watanabe Y, Suzuki H, Sunakawa Y, Shimada K, Kawara K, Sasaki Y and Kato Y. Direct inhibition and down-regulation by uremic plasma components of hepatic uptake transporter for SN-38, an active metabolite of irinotecan, in humans. *Pharm Res* 31(1):204-215, 2014. (IF₂₀₁₃ = 4.742)
- 7) Nakamichi N, Shima H, Asano S, Ishimoto T, Sugiura T, Matsubara K, Kusuhara H, Sugiyama Y, Sai Y, Miyamoto KI, Tsuji A, Kato Y. Involvement of carnitine/organic cation transporter OCTN1/SLC22A4 in gastrointestinal absorption of metformin. *J Pharm Sci* 102(9): 3407-3417, 2013. (IF = 3.130)
- 8) Shitara Y, Nakamichi N, Norioka M, Shima H, Kato Y, Horie T. Role of organic cation/carnitine transporter 1 in uptake of phenformin and inhibitory effect on complex I respiration in mitochondria. *Toxicol Sci* 132(1): 32-42, 2013. (IF = 4.328)
- 9) Hashimoto N, Nakamichi N, Uwafuji S, Yoshida K, Sugiura T, Tsuji A, Kato Y. ATP binding cassette transporters in two distinct compartments of skin contribute to transdermal absorption of a typical substrate. *J Controlled Rel* 165(1): 54-61, 2013. (IF = 7.633)
- 10) Nakamichi N, Taguchi T, Hosotani H, Wakayama T, Shimizu T, Sugiura T, Iseki S, Kato Y. Functional expression of carnitine/organic cation transporter OCTN1 in mouse brain neurons: Possible involvement in neuronal differentiation. *Neurochem Int* 61(7): 1121-1132, 2012. (IF = 2.659)
- 11) Furuichi Y, Sugiura T, Kato Y, Takakura H, Hanai Y, Hashimoto T, Masuda K. Muscle contraction increases carnitine uptake via translocation of OCTN2. *Biochem Biophys Res Commun* 418(4): 774-779, 2012. (IF = 2.406)
- 12) Takeuchi K, Sugiura T, Umeda S, Matsubara K, Horikawa M, Nakamichi N, Silver DL, Ishiwata N, Kato Y. Pharmacokinetics and hepatic uptake of eltrombopag, a novel platelet-Increasing agent. *Drug Metab Dispos* 39(6):1088-1096, 2011. (IF = 3.733)
- 13) Sugiura T, Otake T, Shimizu T, Wakayama T, Silver DL, Utsumi R, Nishimura T, Iseki S, Nakamichi N, Kubo Y, Tsuji A, Kato Y. PDZK1 regulates organic anion transporting polypeptide Oatp1a in mouse small intestine. *Drug Metab Pharmacokinet* 25(6): 588-598, 2010. (IF₂₀₀₉ = 2.544)
- 14) Meng Q, Liu Q, Wang C, Sun H, Kaku T, Kato Y, Liu K. Molecular mechanisms of biliary excretion of cefditoren and the effects of cefditoren on the expression levels of hepatic transporters. *Drug Metab Pharmacokinet* 25(4): 320-327, 2010. (IF₂₀₀₉ = 2.544)
- 15) Sugiura T, Kato S, Shimizu T, Wakayama T, Nakamichi N, Kubo Y, Iwata D, Suzuki K, Soga T, Asano M, Iseki S, Tamai I, Tsuji A, Kato Y. Functional expression of carnitine/organic cation transporter OCTN1/SLC22A4 in mouse small intestine and liver. *Drug Metab Dispos* 38(10): 1665-1672, 2010. (IF₂₀₀₉ = 3.743)

- 16) Furuichi Y, Sugiura T, Kato Y, Shimada Y, Masuda K. OCTN2 is associated with carnitine transport capacity of rat skeletal muscles. *Acta Physiol* **200**(1): 57-64, 2010. (IF₂₀₀₉ = 2.810)
- 17) Mitsuoka K, Kato Y, Miyoshi S, Murakami Y, Hiraiwa M, Kubo Y, Nishimura S, Tsuji A. Inhibition of oligopeptide transporter suppress growth of human pancreatic cancer cells. *Eur J Pharm Sci* **40**(3): 202-208, 2010. (IF₂₀₀₉ = 2.608)
- 18) Kato Y, Kubo Y, Iwata D, Kato S, Sudo T, Sugiura T, Kagaya T, Wakayama T, Hirayama A, Sugimoto M, Sugihara K, Kaneko S, Soga T, Asano M, Tomita M, Matsui T, Wada M, Tsuji A. Gene knockout and metabolome analysis of carnitine/organic cation transporter OCTN1. *Pharm Res* **27**(5): 832-840, 2010. (IF₂₀₀₉ = 3.933)
- 19) Kato S, Kato Y, Nakamura T, Sugiura T, Kubo Y, Deguchi Y, Tsuji A. Genetic deficiency of carnitine/organic cation transporter 2 (slc22a5) is associated with altered tissue distribution of its substrate pyrilamine in mice. *Biopharm Drug Dispos* **30**(9): 495-507, 2009. (IF = 1.246)
- 20) Mitsuoka K, Tamai I, Morohashi Y, Kubo Y, Saitoh R, Tsuji A, Kato Y. Direct evidence for efficient transport and minimal metabolism of L-Cephalexin by PEPT1 in budded baculovirus fraction. *Biol Pharm Bull* **32**(8): 1459-1461, 2009. (IF = 1.810)
- 21) Kato S, Ito K, Kato Y, Wakayama T, Kubo Y, Iseki S, Tsuji A. Involvement of multidrug resistance-associated protein 1 in intestinal toxicity of methotrexate. *Pharm Res* **26**(6): 1467-1476, 2009. (IF = 3.933)
- 22) Kano T, Kato Y, Ito K, Ogihara T, Kubo Y, Tsuji A. Carnitine/organic cation transporter OCTN2 (Slc22a5) is responsible for renal secretion of cephaloridine in mice. *Drug Metab Dispos* **37**(5): 1009-1016, 2009. (IF = 3.743)
- 23) Kato Y, Miyazaki T, Kano T, Sugiura T, Kubo Y, Tsuji A. Involvement of influx and efflux transport systems in gastrointestinal absorption of celiprolol. *J Pharm Sci* **98**(7): 2529-2539, 2009. (IF = 2.906)
- 24) Ito K, Nguyen H-T, Kato Y, Wakayama T, Kubo Y, Iseki S, Tsuji A. P-Glycoprotein (Abcb1) is involved in absorptive drug transport in skin. *J Controlled Rel* **131**(3): 198-204, 2008. (IF = 5.690)
- 25) Nakamura K, Ito K, Kato Y, Sugaya T, Kubo Y, Tsuji A. L-type fatty acid binding protein transgenic mouse as a novel tool to explore cytotoxicity to renal proximal tubules. *Drug Metab Pharmacokinet* **23**(4): 271-278, 2008. (IF = 2.641)
- 26) Nishimura T, Kato Y, Amano N, Ono M, Kubo Y, Kimura Y, Fujita H, Tsuji A. Species difference in intestinal absorption mechanism of etoposide and digoxin between cynomolgus monkey and rat. *Pharm Res* **25**(11): 2467-2476, 2008. (IF = 4.024)
- 27) Mitsuoka K, Miyoshi S, Kato Y, Murakami Y, Utsumi R, Kubo Y, Hiraiwa M, Noda A, Nakamura Y, Nishimura S, Tsuji A. Cancer detection using a PET tracer, ¹¹C-glycylsarcosine, targeted to H⁺/peptide transporter. *J Nucl Med* **49**(4): 615-622, 2008 and **Cover Caption of Vol. 49(4), 2008.** (IF = 6.662)
- 28) Kato Y, Takahara S, Kato S, Kubo Y, Sai Y, Tamai I, Yabuuchi H, Tsuji A. Involvement of multidrug resistance-associated protein 2 (Abcc2) in molecular weight-dependent biliary excretion of β-lactam antibiotics. *Drug Metab Dispos* **36**(6): 1088-1096, 2008. (IF = 3.835)
- 29) Iwata D, Kato Y, Wakayama T, Sai Y, Kubo Y, Iseki S, Tsuji A. Involvement of carnitine/organic cation transporter OCTN2 (SLC22A5) in distribution of its substrate carnitine to the heart. *Drug Metab Pharmacokin* **23**(3): 207-215, 2008. (IF = 2.641)
- 30) Nishimura T, Amano N, Kubo Y, Ono M, Kato Y, Fujita H, Kimura Y, Tsuji A. Asymmetric intestinal first-pass metabolism causes minimal oral bioavailability of midazolam in cynomolgus monkey. *Drug Metab Dispos* **35**(8): 1275-1284, 2007. (IF = 3.907)
- 31) Ito K, Kato Y, Tsuji H, Nguyen HT, Kubo Y, Tsuji A. Involvement of organic anion transport system in transdermal absorption of flurbiprofen. *J Controlled Rel* **124**(1-2): 60-68, 2007. (IF = 4.756)
- 32) Yagi Y, Aoki M, Iguchi M, Shibasaki S, Kurosawa T, Kato Y, Tsuji A. Transporter-mediated hepatic uptake of ulifloxacin, an active metabolite of a prodrug-type new quinolone antibiotic prulifloxacin in rats. *Drug Metab Pharmacokinet* **22**(5): 350-357, 2007. (IF₂₀₀₈ = 2.641)
- 33) Mitsuoka K, Kato Y, Kubo Y, Tsuji A. Functional expression of stereoselective metabolism of cephalexin by exogenous transfection of oligopeptide transporter PEPT1. *Drug Metab Dispos* **35**(3): 356-362, 2007. (IF = 3.907)

- 34) Nishimura T, Kubo Y, Kato Y, Sai Y, Ogihara T, Tsuji A. Characterization of the uptake mechanism for a novel loop diuretic, M17055, in Caco-2 cells: Involvement of organic anion transporting polypeptide (OATP)-B. *Pharm Res* **24**(1): 90-98, 2007. (IF = 2.678)
- 35) Kato Y, Sugiura M, Sugiura T, Wakayama T, Kubo Y, Kobayashi D, Sai Y, Tamai I, Iseki S, Tsuji A. Organic cation/carnitine transporter OCTN2 (Slc22a5) is responsible for carnitine transport across apical membranes of small intestinal epithelial cells in mouse. *Mol Pharmacol* **70**(3): 829-837, 2006. (IF = 4.469)
- 36) Li Q, Tsuji H, Kato Y, Sai Y, Kubo Y, Tsuji A. Characterization of the Transdermal Transport of Flurbiprofen and Indomethacin. *J Control Rel* **110**(3): 542-556, 2006. (IF = 4.012)
- 37) Sai Y, Kato Y, Nakamura K, Kato S, Nishimura T, Kubo Y, Tamai I, Yang S, Hu Z, Yamada I, Tsuji A. Carrier-mediated hepatic uptake of a novel non-renal excretion type uric acid generation inhibitor, Y-700. *J Pharm Sci* **95**(2): 336-347, 2006. (IF = 2.228)
- 38) Sai Y, Kaneko Y, Ito S, Mitsuoka K, Kato Y, Tamai I, Artursson P, Tsuji A. Predominant contribution of organic anion transporting polypeptide OATP-B (OATP2B1) to apical uptake of estrone-3-sulfate by human intestinal Caco-2 cells. *Drug Metab Dispos* **34**(8): 1423-1431, 2006 and **Cover Caption of Vol. 34(8), 2006**. (IF = 3.638)
- 39) Li Q, Kato Y, Sai Y, Imai T, Tsuji A. Multidrug resistance-associated protein 1 functions as an efflux pump of xenobiotics in the skin. *Pharm Res* **22**(6): 842-846, 2005. (IF = 2.752)
- 40) Sasabe H, Kato Y, Suzuki T, Itose M, Miyamoto G, Sugiyama Y. Carrier-mediated uptake of grepafloxacin, a fluoroquinolone antibiotic, by the isolated rat lung cells. *Drug Metab Pharmacokinet* **20**(6): 491-495, 2005. (IF₂₀₀₈ = 2.641)
- 41) Kawasaki Y, Kato Y, Sai Y, Tsuji A. Functional characterization of human organic cation transporter OCTN1 single nucleotide polymorphisms in the Japanese population. *J Pharm Sci* **93**(12): 2920-2926, 2004. (IF = 2.180)
- 42) Sasabe H, Kato Y, Suzuki T, Itose M, Miyamoto G, Sugiyama Y. Differential involvement of multidrug resistance-associated protein 1 and p-glycoprotein in tissue distribution and excretion of grepafloxacin in mice. *J Pharmacol Exp Ther* **310**(2): 648-655, 2004. (IF = 4.335)
- 43) Nishimura T, Kato Y, Sai Y, Ogihara T, Tsuji A. Characterization of renal excretion mechanism for a novel diuretic, M17055, in rats. *J Pharm Sci* **93**(10): 2558-2566, 2004. (IF = 2.180)
- 44) Inano A, Sai Y, Kato Y, Tamai I, Ishiguro M, Tsuji A. Functional regions of organic cation/carnitine transporter OCTN2 (SLC22A5): roles in carnitine recognition. *Drug Metab Pharmacokinet* **19**(3): 180-189, 2004. (IF₂₀₀₈ = 2.641)
- 45) Li Q, Sai Y, Kato Y, Muraoka H, Tamai I, Tsuji A. Transporter-mediated renal handling of nafamostat mesilate. *J Pharm Sci* **93**(2): 262-272, 2004. (IF = 2.180)
- 46) Yagi Y, Shibusaki S, Hodoshima N, Ishiwata K, Okudaira N, Li Q, Sai Y, Kato Y, Tsuji A. Involvement of multiple transport systems in the disposition of an active metabolite of a prodrug-type new quinolone antibiotic, prulifloxacin. *Drug Metab Pharmacokinet* **18**(6): 381-389, 2003. (IF₂₀₀₈ = 2.641)
- 47) Li Q, Sai Y, Kato Y, Tamai I, Tsuji A. Influence of drugs and nutrients on transporter gene expression levels in Caco-2 and LS180 intestinal epithelial cell lines. *Pharm Res* **20**(8): 1119-1124, 2003. (IF = 2.609)
- 48) Wang DS, Kusuhashi H, Kato Y, Jonker JW, Schinkel AH, Sugiyama Y. Involvement of organic cation transporter 1 in the lactic acidosis caused by metformin. *Mol Pharmacol* **63**(4): 844-848, 2003. (IF = 5.650)
- 49) Shitara Y, Li AP, Kato Y, Lu C, Ito K, Itoh T, Sugiyama Y. Function of uptake transporters for taurocholate and estradiol 17beta-d-glucuronide in cryopreserved human hepatocytes. *Drug Metab Pharmacokinet* **18**(1): 33-41, 2003. (IF₂₀₀₈ = 2.641)
- 50) Horikawa M, Kato Y, Tyson CA, Sugiyama Y. Potential cholestatic activity of various therapeutic agents assessed by bile canalicular membrane vesicles isolated from rats and humans. *Drug Metab Pharmacokinet* **18**(1): 16-22, 2003. (IF₂₀₀₈ = 2.641)
- 51) Suzuki T, Kato Y, Sasabe H, Itose M, Miyamoto G, Sugiyama Y. Mechanism for the tissue distribution of grepafloxacin, a fluoroquinolone antibiotic, in rats. *Drug Metab Dispos* **30**(12): 1393-1399, 2002. (IF = 3.277)

- 52) Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y. Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. *J Pharmacol Exp Ther* **302**(2): 510-515, 2002. (IF = 3.991)
- 53) Kato Y, Kuge K, Kusuhara H, Meier PJ, Sugiyama Y. Gender difference in the urinary excretion of organic anions in rats. *J Pharmacol Exp Ther* **302**(2): 483-489, 2002. (IF = 3.991)
- 54) Gotoh Y, Kato Y, Stieger B, Meier PJ, Sugiyama Y. Gender difference in the Oatp1-mediated tubular reabsorption of estradiol 17beta-D-glucuronide in rats. *Am J Physiol* **282**(6): E1245-E1254, 2002. (IF = 3.620)
- 55) Shitara Y, Sugiyama D, Kusuhara H, Kato Y, Abe T, Meier PJ, Itoh T, Sugiyama Y. Comparative inhibitory effects of different compounds on rat oatpl (slc21a1)- and Oatp2 (Slc21a5)-mediated transport. *Pharm Res* **19**(2): 147-153, 2002. (IF = 2.354)
- 56) Horikawa M, Kato Y, Sugiyama Y. Reduced gastrointestinal toxicity following inhibition of the biliary excretion of irinotecan and its metabolites by probenecid in rats. *Pharm Res* **19**(9): 1345-1353, 2002. (IF = 2.354)
- 57) Horikawa M, Kato Y, Tyson CA, Sugiyama Y. The potential for an interaction between MRP2 (ABCC2) and various therapeutic agents: probenecid as a candidate inhibitor of the biliary excretion of irinotecan metabolites. *Drug Metab Pharmacokinet* **17**(1): 23-33, 2002. (IF₂₀₀₈ = 2.641)
- 58) Han YH, Kato Y, Watanabe Y, Terao K, Asoh Y, Sugiyama Y. Carrier-mediated hepatobiliary transport of a novel antifolate, N-[4-[(2,4-dianninopteridine-6-yl)methyl]-3,4-dihydro-2H-1,4- benzothiazin-7-yl]carbonyl-L-homoglutamic acid, in rats. *Drug Metab Dispos* **29**(4 Pt 1): 394-400, 2001. (IF = 2.989)
- 59) Han YH, Kato Y, Haramura M, Ohta M, Matsuoka H, Sugiyama Y. Physicochemical parameters responsible for the affinity of methotrexate analogs for rat canalicular multispecific organic anion transporter (cMOAT/MRP2). *Pharm Res* **18**(5): 579-586, 2001. (IF = 2.801)
- 60) Tsukamoto Y, Kato Y, Ura M, Horii I, Ishitsuka H, Kusuhara H, Sugiyama Y. A physiologically based pharmacokinetic analysis of capecitabine, a triple prodrug of 5-FU, in humans: the mechanism for tumor-selective accumulation of 5-FU. *Pharm Res* **18**(8): 1190-1202, 2001. (IF = 2.801)
- 61) Tsukamoto Y, Kato Y, Ura M, Horii I, Ishikawa T, Ishitsuka H, Sugiyama Y. Investigation of 5-FU disposition after oral administration of capecitabine, a triple-prodrug of 5-FU, using a physiologically based pharmacokinetic model in a human cancer xenograft model: comparison of the simulated 5-FU exposures in the tumour tissue between human and xenograft model. *Biopharm Drug Dispos* **22**(1): 1-14, 2001. (IF = 0.772)
- 62) Ueda K, Kato Y, Komatsu K, Sugiyama Y. Inhibition of biliary excretion of methotrexate by probenecid in rats: quantitative prediction of interaction from in vitro data. *J Pharmacol Exp Ther* **297**(3): 1036-1043, 2001. (IF = 3.555)
- 63) Nishino A, Kato Y, Igarashi T, Sugiyama Y. Both cMOAT/MRP2 and another unknown transporter(s) are responsible for the biliary excretion of glucuronide conjugate of the nonpeptide angiotensin II antagonist, telmisaltan. *Drug Metab Dispos* **28**(10): 1146-1148, 2000. (IF = 2.513)
- 64) Liu KX, Kato Y, Kaku TI, Santa T, Imai K, Yagi A, Ishizu T, Sugiyama Y. Hydroxypropylserine derivatives JBP923 and JBP485 exhibit the antihepatitis activities after gastrointestinal absorption in rats. *J Pharmacol Exp Ther* **294**(2): 510-515, 2000. (IF = 3.452)
- 65) Han YH, Kato Y, Sugiyama Y. Binding and transport of methotrexate and its derivative, MX-68, across the brush-border membrane in rat kidney. *Biopharm Drug Dispos* **20**(8): 361-367, 1999. (IF = 1.068)
- 66) Gotoh Y, Suzuki H, Kinoshita S, Hirohashi T, Kato Y, Sugiyama Y. Involvement of an organic anion transporter (canalicular multispecific organic anion transporter/multidrug resistance- associated protein 2) in gastrointestinal secretion of glutathione conjugates in rats. *J Pharmacol Exp Ther* **292**(1): 433-439, 2000. (IF = 3.452)
- 67) Han YH, Kato Y, Sugiyama Y. Nonlinear disposition kinetics of a novel antifolate, MX-68, in rats. *J Pharmacol Exp Ther* **291**(1): 204-212, 1999. (IF = 3.300)
- 68) Akhteruzzaman S, Kato Y, Kouzuki H, Suzuki H, Hisaka A, Stieger B, Meier PJ, Sugiyama Y. Carrier-mediated hepatic uptake of peptidic endothelin antagonists in rats. *J Pharmacol Exp Ther* **290**(3): 1107-1115, 1999. (IF = 3.300)
- 69) Kino I, Kato Y, Lin JH, Sugiyama Y. Renal handling of biphosphonate alendronate in rats. *Biopharm Drug Dispos* **20**(4): 193-198, 1999. (IF = 1.068)

- 70) Han YH, Kato Y, Kusuhara H, Suzuki H, Shimoda M, Kokue E, Sugiyama Y. Kinetic profile of overall elimination of 5-methyltetrahydropteroylglutamate in rats. *Am J Physiol* **276**(3 Pt 1): E580-E587, 1999. (IF = 2.980)
- 71) Sasabe H, Kato Y, Terasaki T, Tsuji A, Sugiyama Y. Differences in the hepatobiliary transport of two quinolone antibiotics, grepafloxacin and lomefloxacin, in the rat. *Biopharm Drug Dispos* **20**(3): 151-158, 1999. (IF = 1.068)
- 72) Niinuma K, Kato Y, Suzuki H, Tyson CA, Weizer V, Dabbs JE, Froehlich R, Green CE, Sugiyama Y. Primary active transport of organic anions on bile canalicular membrane in humans. *Am J Physiol* **276**(5 Pt 1): G1153-G1164, 1999. (IF = 3.228)
- 73) Akhteruzzaman S, Kato Y, Hisaka A, Sugiyama Y. Primary active transport of peptidic endothelin antagonists by rat hepatic canalicular membrane. *J Pharmacol Exp Ther* **288**(2): 575-581, 1999. (IF = 3.300)
- 74) Kato Y, Akhteruzzaman S, Hisaka A, Sugiyama Y. Hepatobiliary transport governs overall elimination of peptidic endothelin antagonists in rats. *J Pharmacol Exp Ther* **288**(2): 568-574, 1999. (IF = 3.300)
- 75) Chu XY, Kato Y, Sugiyama Y. Possible involvement of P-glycoprotein in biliary excretion of CPT-11 in rats. *Drug Metab Dispos* **27**(4): 440-441, 1999. (IF = 2.519)
- 76) Chu XY, Suzuki H, Ueda K, Kato Y, Akiyama S, Sugiyama Y. Active efflux of CPT-11 and its metabolites in human KB-derived cell lines. *J Pharmacol Exp Ther* **288**(2): 735-741, 1999. (IF = 3.300)
- 77) Sasabe H, Kato Y, Tsuji A, Sugiyama Y. Stereoselective hepatobiliary transport of the quinolone antibiotic grepafloxacin and its glucuronide in the rat. *J Pharmacol Exp Ther* **284**(2): 661-668, 1998. (IF = 3.051)
- 78) Yamada T, Kato Y, Kusuhara H, Lemaire M, Sugiyama Y. Characterization of the transport of a cationic octapeptide, octreotide, in rat bile canalicular membrane: possible involvement of P-glycoprotein. *Biol Pharm Bull* **21**(8): 874-878, 1998. (IF = 0.823)
- 79) Chu XY, Kato Y, Ueda K, Suzuki H, Niinuma K, Tyson CA, Weizer V, Dabbs JE, Froehlich R, Green CE, Sugiyama Y. Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters. *Cancer Res* **58**(22): 5137-5143, 1998. (IF = 8.370)
- 80) Niinuma K, Takenaka O, Horie T, Kobayashi K, Kato Y, Suzuki H, Sugiyama Y. Kinetic analysis of the primary active transport of conjugated metabolites across the bile canalicular membrane: comparative study of S-(2,4-dinitrophenyl)-glutathione and 6-hydroxy-5,7-dimethyl-2-methylamino-4-(3-pyridylmethyl)benzothiazole glucuronide. *J Pharmacol Exp Ther* **282**(2): 866-872, 1997. (IF = 3.227)
- 81) Shin HC, Kato Y, Yamada T, Niinuma K, Hisaka A, Sugiyama Y. Hepatobiliary transport mechanism for the cyclopentapeptide endothelin antagonist BQ-123. *Am J Physiol* **272**(5 Pt 1): G979-G986, 1997. (IF₁₉₉₉ = 3.228)
- 82) Masuda M, Iizuka Y, Yamazaki M, Nishigaki R, Kato Y, Niinuma K, Suzuki H, Sugiyama Y. Methotrexate is excreted into the bile by canalicular multispecific organic anion transporter in rats. *Cancer Res* **57**(16): 3506-3510, 1997. (IF = 8.426)
- 83) Chu XY, Kato Y, Sugiyama Y. Multiplicity of biliary excretion mechanisms for irinotecan, CPT-11, and its metabolites in rats. *Cancer Res* **57**(10): 1934-1938, 1997. (IF = 8.426)
- 84) Chu XY, Kato Y, Niinuma K, Sudo KI, Hokusui H, Sugiyama Y. Multispecific organic anion transporter is responsible for the biliary excretion of the camptothecin derivative irinotecan and its metabolites in rats. *J Pharmacol Exp Ther* **281**(1): 304-314, 1997. (IF = 3.227)
- 85) Shin HC, Kato Y, Shitara Y, Yamada T, Nakamura T, Hisaka A, Sugiyama Y. The endothelin receptor is a major determinant for the nonlinear tissue distribution of the endothelin antagonist BQ-123. *J Pharmacol Exp Ther* **278**(2): 607-613, 1996. (IF = 3.432)

<Protein-protein Interaction for Transporters and Other Membrane Proteins >

- 86) Kawase A, Sakata M, Yada N, Nakasaka M, Shimizu T, Kato Y, Iwaki M. Decreased radixin function for ABC transporters in liver in adjuvant-induced arthritis rats. *J Pharm Sci* **103**(12): 4058-4065, 2014.
- 87) Kawase A, Norikane S, Okada A, Adachi M, Kato Y, Iwaki M. Distinct Alterations in ABC Transporter Expression in Liver, Kidney, Small Intestine, and Brain in Adjuvant-induced Arthritic Rats. *J Pharm Sci* **103**(8): 2556-2564, 2014.

- 88) Yano K, Tomono T, Sakai R, Kano T, Morimoto K, Kato Y, Ogihara T. Contribution of radixin to P-glycoprotein expression and transport activity in mouse small intestine *in vivo*. *J Pharm Sci* **102**(8): 2875-2881, 2013. (IF = 3.130)
- 89) Shimizu T, Sugiura T, Wakayama T, Kijima A, Nakamichi N, Iseki S, Silver DL, Kato Y. PDZK1 regulates breast cancer resistance protein in small intestine. *Drug Metab Dispos* **39**(11): 2148-2154, 2011. (IF = 3.733)
- 90) Kano T, Wada S, Morimoto K, Kato Y, Ogihara T. Effect of knockdown of ezrin, radixin and moesin on P-glycoprotein function in HepG2 cells. *J Pharm Sci* **100**(12): 5308-5314, 2011. (IF = 3.055)
- 91) Kato Y, Sugiura T, Nakadera Y, Sugiura M, Kubo Y, Sato T, Harada A, Tsuji A. Investigation of the role of oligopeptide transporter PEPT1 and sodium/glucose cotransporter SGLT1 in intestinal absorption of their substrates using small GTP-binding protein Rab8 null mice. *Drug Metab Dispos* **37**(3): 602-607, 2009. (IF = 3.743)
- 92) Sugiura T, Kato Y, Wakayama T, Silver DL, Kubo Y, Iseki S, Tsuji A. PDZK1 regulates two intestinal solute carriers (Slc15a1 and Slc22a5) in mice. *Drug Metab Dispos* **36**(6): 1181-1188, 2008. (IF = 3.835)
- 93) Utsunomiya H, Katoono R, Yui N, Sugiura T, Kubo Y, Kato Y, Tsuji A. Cationic polyrotaxanes effectively inhibit uptake via carnitine/organic cationic transporter without cytotoxicity. *Macromol Biosci* **8**(7): 665-669, 2008. (IF = 3.298)
- 94) Sato T, Mushiake S, Kato Y, Sato K, Sato M, Takeda N, Ozono K, Miki K, Kubo Y, Tsuji A, Harada R, Harada A. The Rab8 GTPase regulates apical protein localization in intestinal cells. *Nature* **448**(7151): 366-369, 2007. (IF = 26.681)
- 95) Watanabe C, Kato Y, Sugiura T, Kubo Y, Wakayama T, Iseki S, Tsuji A. PDZ adaptor protein PDZK2 stimulates transport activity of organic cation/carnitine transporter OCTN2 by modulating cell-surface expression. *Drug Metab Dispos* **34**(11): 1927-1934, 2006 and **Cover Caption of Vol. 34(11), 2006**. (IF = 3.638)
- 96) Sugiura T, Kato Y, Kubo Y, Tsuji A. Mutation in an adaptor protein PDZK1 affects transport activity of organic cation transporter OCTNs and oligopeptide transporter PEPT2. *Drug Metab Pharmacokin* **21**(5): 375-383, 2006. (IF₂₀₀₈ = 2.641)
- 97) Watanabe C, Kato Y, Ito S, Kubo Y, Sai Y, Akira Tsuji. Na⁺/H⁺ exchanger 3 affects transport property of H⁺/oligopeptide transporter 1. *Drug Metab Pharmacokin* **20**(6): 443-451, 2005. (IF₂₀₀₈ = 2.641)
- 98) Kato Y, Sai Y, Yoshida K, Watanabe C, Hirata T, Tsuji A. PDZK1 directly regulates the function of organic cation/carnitine transporter OCTN2. *Mol Pharmacol* **67**(3): 734-743, 2005. (IF = 3.622)
- 99) Kato Y, Yoshida K, Watanabe C, Sai Y, Tsuji A. Screening of the interaction between xenobiotic transporters and PDZ proteins. *Pharm Res* **21**(10): 1886-1894, 2004. (IF = 2.940)
- 100) Janvier K, Kato Y, Boehm M, Rose JR, Martina JA, Kim BY, Venkatesan S, Bonifacino JS. Recognition of dileucine-based sorting signals from HIV-1 Nef and LIMP-II by the AP-1 gamma-sigma1 and AP-3 delta-sigma3 hemicomplexes. *J Cell Biol* **163**(6): 1281-1290, 2003. (IF = 10.152)
- 101) Kato Y, Misra S, Puertollano R, Hurley JH, Bonifacino JS. Phosphoregulation of sorting signal-VHS domain interactions by a direct electrostatic mechanism. *Nat Struct Biol* **9**(7): 532-536, 2002. (IF = 11.502)
- 102) Misra S, Puertollano R, Kato Y, Bonifacino JS, Hurley JH. Structural basis for acidic-cluster-dileucine sorting-signal recognition by VHS domains. *Nature* **415**(6874): 933-937, 2002. (IF = 26.681)

<Pharmacokinetics and Drug Delivery System for Macromolecular Compounds>

- 103) Adachi E, Hirose-Sugiura T, Kato Y, Ikebuchi F, Yamashita A, Abe T, Fukuta K, Adachi K and Matsumoto K. Pharmacokinetics and pharmacodynamics following intravenous administration of recombinant human hepatocyte growth factor in rats with renal injury. *Pharmacology* **94**(3-4): 190-187, 2014.
- 104) Sugiura T, Takahashi S, Sano K, Abe T, Fukuta K, Adachi K, Nakamura T, Matsumoto K, Nakamichi N, Kato Y. Pharmacokinetic modeling of hepatocyte growth factor in experimental animals and humans. *J Pharm Sci* **102**(1): 237-249, 2013. (IF = 3.130)

- 105) Liu KX, Kato Y, Matsumoto K, Nakamura T, Kaku T, Sugiyama Y. Characterization of the enhancing effect of protamine on the proliferative activity of hepatocyte growth factor in rat hepatocytes. *Pharm Res* **26**(4): 1012-1021, 2009. (IF = 3.933)
- 106) Komoriya K, Kato Y, Hayashi Y, Ohsuye K, Nishigaki R, Sugiyama Y. Characterization of the hepatic disposition of lanotepase, a rationally designed variant of tissue plasminogen activator in rodents. *Drug Metab Dispos* **35**(3): 469-475, 2007. (IF = 3.907)
- 107) Nishiyama N, Okazaki S, Cabral H, Miyamoto M, Kato Y, Sugiyama Y, Nishio K, Matsumura Y, Kataoka K. Novel cisplatin-incorporated polymeric micelles can eradicate solid tumors in mice. *Cancer Res* **63**(24): 8977-8983, 2003. (IF = 8.649)
- 108) Maeda K, Kato Y, Sugiyama Y. pH-dependent receptor/ligand dissociation as a determining factor for intracellular sorting of ligands for epidermal growth factor receptors in rat hepatocytes. *J Control Rel* **82**(1): 71-82, 2002. (IF = 3.131)
- 109) Sato H, Kato Y, Hayasi E, Tabata T, Suzuki M, Takahara Y, Sugiyama Y. A novel hepatic-targeting system for therapeutic cytokines that delivers to the hepatic asialoglycoprotein receptor, but avoids receptor-mediated endocytosis. *Pharm Res* **19**(11): 1736-1744, 2002. (IF = 2.354)
- 110) Shirota K, Kato Y, Suzuki K, Sugiyama Y. Characterization of novel kidney-specific delivery system using an alkylglucoside vector. *J Pharmacol Exp Ther* **299**(2): 459-467, 2001. (IF = 3.555)
- 111) Mizuno N, Kato Y, Iwamoto M, Urae A, Amamoto T, Niwa T, Sugiyama Y. Kinetic analysis of the disposition of insulin-like growth factor 1 in healthy volunteers. *Pharm Res* **18**(8):1203-1209, 2001. (IF = 2.801)
- 112) Yamamoto Y, Nagasaki Y, Kato Y, Sugiyama Y, Kataoka K. Long-circulating poly(ethylene glycol)-poly(D,L-lactide) block copolymer micelles with modulated surface charge. *J Control Rel* **77**(1-2): 27-38, 2001. (IF = 2.626)
- 113) Nishiyama N, Kato Y, Sugiyama Y, Kataoka K. Cisplatin-loaded polymer-metal complex micelle with time-modulated decaying property as a novel drug delivery system. *Pharm Res* **18**(7): 1035-1041, 2001. (IF = 2.801)
- 114) Kato M, Kato Y, Sugiyama Y. Mechanism of the upregulation of erythropoietin-induced uptake clearance by the spleen. *Am J Physiol* **276**(5 Pt 1): E887-E895, 1999. (IF = 2.980)
- 115) Kato M, Kato Y, Nakamura T, Sugiyama Y. Efficient extraction by the liver governs overall elimination of hepatocyte growth factor in rats. *J Pharmacol Exp Ther* **290**(1): 373-379, 1999. (IF = 3.300)
- 116) Liu KX, Kato Y, Kino I, Nakamura T, Sugiyama Y. Ligand-induced downregulation of receptor-mediated clearance of hepatocyte growth factor in rats. *Am J Physiol* **275**(5 Pt 1): E835-E842, 1998. (IF₁₉₉₉ = 2.980)
- 117) Kato M, Miura K, Kamiyama H, Okazaki A, Kumaki K, Kato Y, Sugiyama Y. Pharmacokinetics of erythropoietin in genetically anemic mice. *Drug Metab Dispos* **26**(2): 126-131, 1998. (IF = 2.271)
- 118) Shitara Y, Kato Y, Sugiyama Y. Effect of brefeldin A and lysosomotropic reagents on intracellular trafficking of epidermal growth factor and transferrin in Madin-Darby canine kidney epithelial cells. *J Control Rel* **55**(1): 35-43, 1998. (IF = 1.894)
- 119) Liu KX, Kato Y, Kaku TI, Matsumoto K, Nakamura T, Sugiyama Y. Protamine enhances the proliferative activity of hepatocyte growth factor in rats. *Am J Physiol* **274**(1 Pt 1): G21-G28, 1998. (IF₁₉₉₉ = 3.228)
- 120) Kato M, Kamiyama H, Okazaki A, Kumaki K, Kato Y, Sugiyama Y. Mechanism for the nonlinear pharmacokinetics of erythropoietin in rats. *J Pharmacol Exp Ther* **283**(2): 520-527, 1997. (IF = 3.227)
- 121) Kato M, Miura K, Kamiyama H, Okazaki A, Kumaki K, Kato Y, Sugiyama Y. Immunological response to repeated administration of recombinant human erythropoietin in rats: biphasic effect on its pharmacokinetics. *Drug Metab Dispos* **25**(9): 1039-1044, 1997. (IF = 2.356)
- 122) Liu KX, Kato Y, Kato M, Kaku TI, Nakamura T, Sugiyama Y. Existence of two nonlinear elimination mechanisms for hepatocyte growth factor in rats. *Am J Physiol* **273**(5 Pt 1): E891-E897, 1997. (IF₁₉₉₉ = 2.980)

- 123) Koza A, Kato Y, Shitara Y, Hanano M, Sugiyama Y. Kinetic analysis of transcytosis of epidermal growth factor in Madin-Darby canine kidney epithelial cells. *Pharm Res* **14**(9): 1228-1235, 1997. (IF = 2.204)
- 124) Hamada T, Kato Y, Terasaki T, Sugiyama Y. Cell density-dependent mitogenic effect and -independent cellular handling of epidermal growth factor in primary cultured rat hepatocytes. *J Hepatol* **26**(2): 353-360, 1997. (IF = 3.409)
- 125) Liu KX, Kato Y, Terasaki T, Aoki S, Okumura K, Nakamura T, Sugiyama Y. Contribution of parenchymal and non-parenchymal liver cells to the clearance of hepatocyte growth factor from the circulation in rats. *Pharm Res* **12**(11): 1737-1740, 1995. (IF = 2.060)
- 126) Liu KX, Kato Y, Terasaki T, Nakamura T, Sugiyama Y. Change in hepatic handling of hepatocyte growth factor during liver regeneration in rats. *Am J Physiol* **269**(5 Pt 1): G745-G753, 1995. (IF₁₉₉₉ = 3.228)
- 127) Kato Y, Liu KX, Nakamura T, Sugiyama Y. Heparin-hepatocyte growth factor complex with low plasma clearance and retained hepatocyte proliferating activity. *Hepatology* **20**(2): 417-424, 1994. (IF = 5.569)
- 128) Ichikawa M, Kato Y, Miyauchi S, Sawada Y, Iga T, Fuwa T, Hanano M, Sugiyama Y. Effect of perfusate pH on the influx of 5-5'-dimethyl-oxazolidine-2,4-dione and dissociation of epidermal growth factor from the cell-surface receptor: the existence of the proton diffusion barrier in the Disse space. *J Hepatol* **20**(2): 190-200, 1994. (IF = 3.154)
- 129) 103) Liu KX, Kato Y, Yamazaki M, Higuchi O, Nakamura T, Sugiyama Y. Decrease in the hepatic clearance of hepatocyte growth factor in carbon tetrachloride-intoxicated rats. *Hepatology* **17**(4): 651-660, 1993. (IF₂₀₀₄ = 5.569)
- 130) Kato Y, Sugiyama Y. Binding, internalization, degradation, and mitogenic effect of epidermal growth factor in cultured rat hepatocytes. *STP Pharm Sci* **3**(1): 75-82, 1993. (IF₁₉₉₆ = 0.543)
- 131) Liu KX, Kato Y, Narukawa M, Kim DC, Hanano M, Higuchi O, Nakamura T, Sugiyama Y. Importance of the liver in plasma clearance of hepatocyte growth factors in rats. *Am J Physiol* **263**(5 Pt 1): G642-G649, 1992. (IF₁₉₉₉ = 3.228)
- 132) Kato Y, Sato H, Ichikawa M, Suzuki H, Sawada Y, Hanano M, Fuwa T, Sugiyama Y. Existence of two pathways for the endocytosis of epidermal growth factor by rat liver: phenylarsine oxide-sensitive and -insensitive pathways. *Proc Natl Acad Sci USA* **89**(18): 8507-8511, 1992. (IF₁₉₉₄ = 10.667)

<Other Research Including Collaboration Studies>

- 133) Naka K, Jomen Y, Ishihara K, Kim J, Ishimoto T, Bae E, Mohney R, Stirdivant SM, Oshima H, Oshima M, Kim DW, Nakauchi H, Takihara Y, Kato Y, Ooshima A, Kim SJ. Dipeptide species regulate nutrient signalling essential for the maintenance of chronic myelogenous leukaemia stem cells. *Nat Commun*, in press.
- 134) Matsuo H, Yamamoto K, Nakaoka H, Nakayama A, Sakiyama M, Chiba T, Takahashi A, Nakamura T, Nakashima H, Takada Y, Danjoh I, Shimizu S, Abe J, Kawamura Y, Terashige S, Ogata H, Tatsukawa S, Yin G, Okada R, Morita E, Naito M, Tokumasu A, Onoue H, Iwaya K, Ito T, Takada T, Inoue K, Kato Y, Nakamura Y, Sakurai Y, Suzuki H, Kanai Y, Hosoya T, Hamajima N, Inoue I, Kubo M, Ichida K, Ooyama H, Shimizu T, Shinomiya N. Genome-wide association study of clinically defined gout identifies multiple risk loci and its association with clinical subtypes. *Ann Rheum Dis*, in press.
- 135) Nakayama A, Matsuo H, Shimizu T, Ogata H, Takada Y, Nakashima H, Nakamura T, Shimizu S, Chiba T, Sakiyama M, Ushiyama C, Takada T, Inoue K, Kawai S, Hishida A, Wakai K, Hamajima N, Ichida K, Sakurai Y, Kato Y, Shimizu T, Shinomiya N. A common missense variant of monocarboxylate transporter 9 (MCT9/SLC16A9) gene is associated with renal overload gout, but not with all gout susceptibility. *Hum Cell* **26**(4): 133-136, 2013. (IF = 1.409)
- 136) Liu H-X, Lopatina O, Higashida C, Fujimoto H, Akther S, Inzhutova A, Liang M, Zhong J, Tsuji T, Yoshihara T, Sumi K, Ishiyama M, Ma W-J, Ozaki M, Yagitani S, Yokoyama S, Mukaida N, Sakurai T, Hori O, Yoshioka K, Hirao A, Kato Y, Ishihara K, Kato I, Okamoto H, Cherepanov SM, Salmina A, Hirai H, Asano M, Brown DA, Nagano I, Higashida H. Displays of mouse pup retrieval as paternal parental behaviour following communicative interaction with maternal mates. *Nat Commun* **4**: 1346, 2013. (IF = 10.015)

- 137) Wakayama T, Sai Y, Ito A, Kato Y, Kurobo M, Murakami Y, Nakashima E, Tsuji A, Kitamura Y, Iseki S. Heterophilic binding of the adhesion molecules poliovirus receptor and immunoglobulin superfamily 4A in the interaction between mouse spermatogenic and Sertoli cells. *Biol Reprod* **76**(6): 1081-1090, 2007. (IF = 3.670)
- 138) Jin M, Shimada T, Yokogawa K, Nomura M, Kato Y, Tsuji A, Miyamoto K. Contributions of intestinal P-glycoprotein and CYP3A to oral bioavailability of cyclosporin A in mice treated with or without dexamethasone. *Int J Pharm* **309**(1-2): 81-86, 2006. (IF = 2.212)
- 139) Jin M, Shimada T, Yokogawa K, Nomura M, Ishizaki J, Piao Y, Kato Y, Tsuji A, Miyamoto K. Site-dependent contributions of P-glycoprotein and CYP3A to cyclosporin A absorption, and effect of dexamethasone in small intestine of mice. *Biochem Pharmacol* **72**(8):1042-1050, 2006. (IF = 3.581)
- 140) Wakayama T, Kato Y, Utsumi R, Tsuji A, Iseki S. A time- and cost-saving method of producing rat polyclonal antibodies. *Acta Histochem Cytochem* **39**(3): 79-87, 2006. (IF = 0.429)
- 141) Shiota K, Kato Y, Irimura T, Kondo H, Sugiyama Y. Anti-metastatic effect of the sialyl Lewis-X analog GSC-150 on the human colon carcinoma derived cell line KM12-HX in the mouse. *Biol Pharm Bull* **24**(3): 316-319, 2001. (IF = 0.820)
- 142) Kawahara I, Kato Y, Suzuki H, Achira M, Ito K, Crespi CL, Sugiyama Y. Selective inhibition of human cytochrome P450 3A4 by N-[2(R)-hydroxy-1(S)-indanyl]-5-[2(S)-(1, 1-dimethylethylaminocarbonyl)-4-[(furo[2, 3-b]pyridin-5-yl)methyl]piperazin-1-yl]-4(S)-hydroxy-2(R)-phenylmethylpentanamide and P-glycoprotein by valspodar in gene transfectant systems. *Drug Metab Dispos* **28**(10): 1238-1243, 2000. (IF = 2.513)
- 143) Mizuno N, Kato Y, Shiota K, Izumi Y, Irimura T, Harashima H, Kiwada H, Motoji N, Shigematsu A, Sugiyama Y. Mechanism of initial distribution of blood-borne colon carcinoma cells in the liver. *J Hepatol* **28**(5): 878-885, 1998. (IF = 3.189)
- 144) Mizuno N, Kato Y, Izumi Y, Irimura T, Sugiyama Y. Importance of hepatic first-pass removal in metastasis of colon carcinoma cells. *J Hepatol* **28**(5): 865-877, 1998. (IF = 3.189)
- 145) Liu KX, Kato Y, Kaku T, Sugiyama Y. Human placental extract stimulates liver regeneration in rats. *Biol Pharm Bull* **21**(1): 44-49, 1998. (IF = 0.823)

2. Review Articles and Book Chapters (Written in English)

- R1) Sugiura T, Umeda S, Tsuji A, Kato Y. PEPT (SLC15A) family In: "Pharmacogenomics of Human Drug Transporters," edited by Ishikawa T, Kim RB, König J, Aptara Inc., pp223-242, 2013.
- R2) Sugiura T, Shimizu T, Kijima A, Minakata S, Kato Y. PDZ adaptors: Their regulation of epithelial transporters and involvement in human diseases. *J Pharm Sci* (review) **100**(9): 3620-3635, 2011. (IF = 3.055)
- R3) Kato Y. Xenobiotic transporter-adaptor network. *Drug Metab Pharmacokin* **22**(6): 401-408, 2007. (IF₂₀₀₈ = 2.641)
- R4) Kato Y, Watanabe C, Tsuji A. Regulation of drug transporters by PDZ adaptor proteins and nuclear receptors. *Eur J Pharm Sci* (review) **27**(5): 487-500, 2006 (IF = 2.482)
- R5) Sugiura T, Kato Y, Tsuji A. Role of SLC xenobiotic transporters and their regulatory mechanisms PDZ proteins in drug delivery and disposition. *J Controlled Rel* (review) **116**(2): 238-246, 2006. (IF = 4.012)
- R6) Kubo Y, Nakamura T, Iwata D, Kato Y, Tsuji A. Functional analysis of organic cation transporter OCTNs in mouse renal brush border membrane. *Pharmazie* **61**(2): 171, 2006. (IF = 0.606)
- R7) Kato Y, Suzuki H, Sugiyama Y. Toxicological implications of hepatobiliary transporters. *Toxicology* (review) **181-182**: 287-290, 2002. (IF = 2.470)
- R8) Sugiyama Y, Kato Y, Chu X. Multiplicity of biliary excretion mechanisms for the camptothecin derivative irinotecan (CPT-11), its metabolite SN-38, and its glucuronide: role of canalicular multispecific organic anion transporter and P-glycoprotein. *Cancer Chemother Pharmacol* **42** Suppl: S44-S49, 1998. (IF = 1.740)

- R9) Kato Y, Sugiyama Y. Peptide and protein delivery targeted to receptor-mediated endocytosis. *Crit Rev Ther Drug Carrier Systems* **14**(3): 173-219, 1997. (IF = 1.692)
- R10) Kato Y, Seita T, Kuwabara Y, Sugiyama Y. Kinetic analysis of receptor-mediated endocytosis (RME) of proteins and peptides: Use of RME as a drug delivery system. *J Controlled Rel* (review) **39**: 191-200, 1996. (IF = 1.674)

3. Editorial and Preface (Written in English)

- E1) Kato Y. Efforts to overcome in vitro/in vivo discrepancy. Editorial. *Drug Metab Pharmacokinet* **24**(5): 409-410, 2009. (IF = 2.544)
- E2) Kato Y, Tamai I. New aspects of transporter research: future may exist "beyond the transport". Preface. *Drug Metab Pharmacokinet* **23**(4): 221-222, 2008. (IF = 2.641)

4. Review Articles and Book Chapters (Written in Japanese)

- J1) 中道範隆、加藤将夫
神経細胞に発現する異物取り込みトランスポーターの役割
ファルマシア (最前線) 51(4): 337-341, 2015.
- J2) 中道範隆、及川真志、加藤将夫
皮膚に発現するトランスポーターとその役割
コスメテックジャパン 4(2): 17-21, 2014. (2014年2月)
- J3) 加藤将夫
トランスポーターと医薬品毒性の複雑な関係
谷本学校毒性質問箱: 他では聞けない、くすり開発現場の基礎知識 (サイエンティスト社), 15号: 41-49, 2013. (2013年9月)
- J4) 杉浦智子、加藤将夫
メタボロミクスによるトランスポーター機能の探索
細胞工学, 31(5) 新たな創薬ターゲットとしてのトランスポーター、金井好克監修
株式会社学研メディカル秀潤社, pp. 546-547 (2012年4月)
- J5) 清水卓也、杉浦智子、加藤将夫
遺伝子欠損マウスのメタボローム解析によるOCTN1 (SLC22A4)の生体内機能の解明
遺伝子医学MOOK (19) トランスポートソーム-生体膜輸送機構の全体像に迫る、
金井好克編
株式会社メディカルドゥ、pp. 77-82 (2011年3月)
- J6) 杉浦智子、加藤将夫
低分子量GTP結合タンパク質Rab8によるSLCトランスポーターを介した消化管吸収制御
遺伝子医学MOOK (19) トランスポートソーム-生体膜輸送機構の全体像に迫る、
金井好克編
株式会社メディカルドゥ、pp. 265-270 (2011年3月)
- J7) 杉浦智子、加藤将夫 有機カチオントランスポーターOCTN1/SLC22A4によるエルゴチオネイン輸送 ビタミン, 84(10): 465-471, 2010.
- J8) 加藤将夫 薬剤学を基盤とする薬物治療学 薬剤学 70(2): 109-114, 2010.
- J9) 杉浦智子、加藤将夫 メタボロミクスによるorphan SLCトランスポーターの生体内基質探索
医薬のあゆみ, 231(12, 13): 1176-1182, 2009.
- J10) 杉浦智子、加藤将夫 薬物動態関連トランスポーターと相互作用するタンパク質 遺伝子医学MOOK (12) 最新トランスポーター研究2009、杉山雄一・金井好克編 株式会社メディカルドゥ、pp. 76-82 (2009年1月)
- J11) 加藤将夫、辻 彰 トランスポーターの細胞内局在メカニズムと薬物動態変動への影響 分子薬物動態学 杉山雄一、楠原洋之編 南山堂、pp. 395-410 (2008年4月)

- J12) 加藤将夫 薬物トランスポーターの上皮細胞頂側膜発現調節に機能するタンパク質の生理・薬理的役割 トランスポーター科学最前線 辻 彰編 京都廣川書店、pp. 57-70 (2008年2月)
- J13) 杉浦智子, 加藤将夫, 辻 彰 膜トランスポーターとタンパク質間相互作用, 生体の科学, 58, 412-414, 2007.
- J14) 加藤将夫、内海理恵、辻 彰 薬物輸送を制御するアダプタータンパク質 遺伝子医学MOOK (7) 最新創薬学2007、杉山雄一編 株式会社メディカルドゥ、pp. 142-148 (2007年4月)
- J15) 松下 良、加藤将夫 新しい剤形：ドラッグデリバリーシステム 新薬剤学 (改訂第2版) 辻 彰編 南江堂、pp. 359-382 (2007年4月)
- J16) 加藤将夫 トランスポーター・アダプターを介した栄養物・薬物の生体膜透過 薬剤学 67(1): 27-31, 2007.
- J17) 加藤将夫 トランスポータータンパク質相互作用と活性調節 創薬動態：医薬品創製のための考え方と最新情報、玉井郁巳編 日本薬物動態学会、pp. 169-175 (2006年12月)
- J18) 加藤将夫 初心者のための動態関連論文投稿のノウハウ 日本薬物動態学会ニュースレター 21(3): 14-19, 2006.
- J19) 加藤将夫、松本 健、辻 彰 薬物トランスポーターと薬剤感受性 (1) -薬物トランスポーターの遺伝的多型とその評価- 最新医学 60(9): 1819-1826, 2005.
- J20) 加藤将夫、辻 彰 糖のトランスポーター, レセプター Drug Delivery System 19(1): 38-44, 2004.
- J21) 加藤将夫、杉山雄一 ファーマコキネティクス立場からみたターゲティングの設計 Drug Delivery System 16(5): 376-383, 2001.
- J22) 加藤将夫、杉山雄一 Pharmacogenomics/Pharmacogeneticsに基づく適正化学療法 Bio Clinica 15(13): 1028-1032, 2000.
- J23) 杉山雄一、加藤将夫 遺伝子多型と抗癌剤の効果・副作用 Cancer Frontier 2(1): 21-27, 2000.
- J24) 杉山雄一、加藤将夫、金光真一、伊藤清美 肝臓での代謝および輸送における薬物間相互作用の定量的予測 薬物動態 15(3): 235-243, 2000.
- J25) 加藤将夫、杉山雄一 レセプター・トランスポーターと薬物ターゲティング 今日のDDS 薬物送達システム 高橋俊雄、橋田 充編集 医薬ジャーナル社、pp. 137-148 (1999年12月).
- J26) 前田和哉、加藤将夫、杉山雄一 阻害剤を用いた細胞内輸送機構の解明と制御 生体の科学 50(6): 539-547, 1999.
- J27) 加藤将夫、杉山雄一 薬物の輸送過程における薬物間相互作用：胆管側膜透過過程における薬物間相互作用(1)(2) Pharm Tech Japan. 15(1): 45-58, 1999; 15(2): 173-185, 1999.
- J28) 加藤将夫、杉山雄一 G-CSF併用による化学療法とbiochemical response modifiers (BRM) 療法 抗癌剤の相互作用：これからの抗癌剤治療戦略、杉山雄一・佐々木康綱編、医薬ジャーナル社、pp. 80-89 (1998年1月).
- J29) 加藤将夫 アニマルスケールアップ 医薬品開発における薬物動態研究、杉山雄一編、薬業時報社、101-168 (1998年3月).
- J30) 設楽悦久、加藤将夫、伊藤清美、伊藤智夫、杉山雄一 薬物の輸送過程における薬物間相互作用：肝臓への取り込み過程における薬物間相互作用 Pharm Tech Japan. 14(13): 2005-2016, 1998.
- J31) 杉山雄一、新沼佳世子、申 豪徹、山田 禎、加藤将夫、中村立二、樋坂章博 有機アニオン性低分子ペプチドの肝における輸送 肝臓病学の最前線、中外医学社、pp. 269-274, 1997.
- J32) 加藤将夫、杉山雄一 レセプター介在性エンドサイトーシスによるサイトカイン類の血中レベルの調節 RADIOISOTOPES 46(9): 693-694, 1997.
- J33) 加藤将夫、杉山雄一 バイオ医薬品とは 薬局48(5): 714-721, 1997.
- J34) 杉山雄一、加藤将夫、鈴木洋史 Drug Delivery System (DDS)と肝臓 肝臓病学の進歩 第23巻別冊: 18-25, 1997.

- J35) 加藤将夫、泉 高司、湯浅博昭、杉山雄一 薬物動態演習 医薬品開発におけるファーマコキネティクス研究の役割 3 : アニマルスケールアップ Pharm Tech Japan 12 (12): 1645-1663, 1996.
- J36) 加藤将夫、杉山雄一 薬毒物のわかりやすい体内動態 -1, 2, 3- 中毒研究 7: 395-403, 1994; 8: 85-97, 1995; 8: 163-178, 1995.
- J37) 加藤将夫、寺崎哲也、杉山雄一 発癌に関するリスクアセスメント : トキシコキネティクス、トキシコダイナミクスの観点から J Toxicol Sci. 19, Appendix 111-124, 1994.
- J38) 加藤将夫、杉山雄一 レセプターを用いたターゲッティング ファルマシア29(11): 1264-1268, 1993.